Prostate Cancer News Archive
In a study, androgen deprivation therapy did not increase risks for vascular or any other form of dementia among men with prostate cancer who underwent definitive radiation therapy.
In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.
A combination of age, comorbidity, and PSA doubling time can risk stratify cause of death among men with non-metastatic castration-resistant prostate cancer, study suggests.
Men in Puerto Rico have higher prostate cancer incidence rates than other Hispanics, non-Hispanic whites.
In a study, men with prostate cancer who received androgen deprivation therapy did not have a lower subsequent risk of developing bladder cancer.
Medium-term oncologic results are comparable to those of radical prostatectomy and radiation therapy, according to investigators.
Only 11% of private insurers in the United States cover prostate MRI in biopsy-naïve patients with suspect prostate cancer.
Radical prostatectomy plus adjuvant radiotherapy is associated with better cancer-specific and overall survival than radiotherapy plus androgen deprivation therapy in patients with locally or regionally advanced prostate cancer.
Men in the highest vs lowest tertile of total cholesterol had a 42% increased risk of Gleason 8-10 prostate cancer, Finnish study finds.
Some prostate cancer cells lack androgen receptor, and they proliferate faster than those that express androgen receptor under androgen-deficient conditions.
A study of 400,887 men in an integrated health system, the first to evaluate various PSA screening intervals and age groups, concluded that yearly screening is the interval of choice.
New analysis of the SPARTAN trial shows that apalutamide maintains health-related quality of life while lowering the risk of metastasis.
Australian study shows 8-year overall survival and biochemical relapse-free rates of 78.4% and 68.1%, respectively.
Men who received androgen deprivation therapy for prostate cancer were 54% more likely to be diagnosed with non-alcoholic fatty liver disease than those who did not, a study found.
The risk being lost to follow-up while on active surveillance for prostate cancer is higher among blacks than whites, according to a study.
LUTS treatment with the alpha-blocker prazosin was associated with significantly lower 2- and 5-year biochemical recurrence rates vs tamsulosin and non-use of alpha-blockers.
Low-dose-rate brachytherapy is associated with excellent long-term biochemical control and survival, new study finds.
Even low cumulative exposure to physical strain at work is associated with a decreased risk of prostate cancer, study finds.
In a study, men with low-risk prostate cancer were nearly 2-fold more likely to be managed with observation if they had a prostate MRI during the diagnostic work-up.
At a major tertiary referral center, the use of radical prostatectomy for insignificant prostate cancer decreased from 15% in 2009 to 3% in 2016, a study found.
A patient's risk of suicide is doubled within the first year following a prostate cancer diagnosis, according to a new meta-analysis.
Study of Korean radical prostatectomy patients showed that those who were obese had significant increased odds of biochemical recurrence and cancer-specific mortality
Cytoreductive radical prostatectomy (RP) for metastatic prostate cancer (PCa) is associated with higher complication rates and longer hospital stays than RP for non-metastatic PCa.
From 2000 to 2015 screening for breast, cervical, and prostate cancers decreased significantly, whereas screening for colorectal cancer increased significantly.
Physicians increasingly are prescribing high dose and very high dose radiation therapy after radical prostatectomy despite an absence of randomized trials supporting the practice.
Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.
Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.
Radiation therapy dose escalation, pelvic lymph node irradiation, and hormone therapy duration are prescribed based on patient and tumor characteristics.
Men in the bottom 10th of free testosterone level vs those with higher levels were found to have a 23% decreased risk of prostate cancer.
Younger men with prostate cancer are less likely to experience Gleason score upgrading and pathologic progression on repeat biopsy.
According to researchers, 57.3% of men who underwent salvage robot-assisted radical prostatectomy were pad-free at 12 months.
New study shows no significant difference in overall survival between 18 and 36 months of androgen deprivation therapy used in combination with radiation therapy.
Regardless of treatment modality, men with Gleason 10 prostate cancer have high 5-year overall survival rates, new study finds.
Early study results are encouraging, but high-quality data that validate PET/CT against a reliable reference standard are lacking.
MRI with targeted prostate biopsy plus systematic biopsy fails to improve detection of upgrading in men on active surveillance for prostate cancer vs systematic biopsy alone.
This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.
Pulmonary embolism is associated with GnRH agonist use and orchiectomy.
The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.
Incidence of tx-emergent small-cell neuroendocrine prostate cancer 17% among those with mCRPC.
Failure-free survival was 88% at 5 years among patients with nonmetastatic prostate cancer who underwent focal therapy with high-intensity focused ultrasound.
aBSI validated as prognostic biomarker of survival in metastatic castration-resistant prostate cancer
More conservative management and active surveillance utilized at VA hospitals from 2005 to 2015.
Metformin plus androgen deprivation therapy is associated with a lower death risk vs ADT alone in men without diabetes, study of US veterans shows.
Men receiving enzalutamide plus ADT had a significant 71% lower risk for metastasis or death compared with men receiving placebo plus ADT.
Children who migrated to the UK from Bangladesh before puberty and Bangladeshis born in the UK had significantly higher levels of testosterone compared with life-long residents of Bangladesh.
In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.
Men with advanced prostate cancer at diagnosis have an elevated risk of spinal cord compression, renal failure, and other cancer-related morbidities.
Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.
Clinicians can rest easier about recommending finasteride to more men, according to experts.
Those with worse emotional distress also report worse urinary, sexual, bowel functions.
If externally validated, bpMRI could be used to triage men for prostate biopsy.
Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.
In 2015, 69% of surgeries for prostate, bladder, and kidney cancer were performed with robotic assistance, a new meta-analysis shows.
Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.
"We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC," said Michael Cookson, MD, member of the 2018 amendment panel.
Findings for men with intermediate- and high-risk prostate cancer.
In a meta-analysis, smokers had an 89% greater risk of dying from prostate cancer compared with nonsmokers.
The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC.
Sharpest decrease seen in privately insured men after 2011.
Men with low-risk PCa who underwent partial gland ablation with vascular-targeted photodynamic therapy were less likely than those on AS to require radical treatment.
The percentage of prostate cancer patients with positive lymph nodes increased from 2.4% in 2010 to 4.7% in 2014.
Men with Peyronie's disease have elevated risks of benign prostatic hyperplasia, prostatitis, and testis and prostate cancer, new studies reveal.
Findings from the largest study to date examining the effect of TRT in prostate cancer patients build on previous evidence showing that the treatment does not affect disease progression risk.
At 1 year post-op, patients with MetS prior to prostate surgery had a significantly lower continence rate than those without MetS (75.4% vs 82.6%).
Extent of disease and change in PSA were the strongest predictors of disease progression in men with chemotherapy-naïve mCRPC treated with abiraterone.
Oncologic outcomes are similar for focal and total cryoablation for localized prostate cancer, but patients report significantly better sexual function after focal cryoablation.
Men on active surveillance for prostate cancer who had a negative confirmatory biopsy experienced an 88% decreased risk of progression to treatment.
Following laparoscopic radical prostatectomy, men with posterior index tumors had 76% increased risk of biochemical recurrence vs those with anterior prostate tumors.
Gleason score at the margin can better stratify biochemical recurrence-free rates, according to study findings.
Men with Gleason 6 and Gleason 3+4 prostate cancer who undergo radical prostatectomy after a period on active surveillance have similar surgical outcomes.
IsoPSA can correctly rule out high-grade prostate cancer 93% of the time and thus has the potential to reduce the number of unnecessary prostate biopsies.
Investigators suggest PSA testing frequencies based on post-operative baseline PSA.
Findings show small increased risk with white wine, decreased risk with red wine
High PSA levels and larger number of positive biopsy cores are associated with positive surgical margins and extracapsular extension/seminal vesicle invasion after radical prostatectomy.
Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.
Prostate and lung cancer expected to emerge as the most common types by 2030.
The new statement emphasizes shared decision-making on screening for men aged 55 to 69 years who are at average risk for prostate cancer.
Canadian study shows that nearly all men undergoing radical prostatectomy in Eastern Ontario in recent years have clinically significant prostate cancer.
Men with Gleason score (GS) 4+3 prostate cancer have a 3-fold higher risk of distant metastasis at diagnosis than those with GS 3+4 PCa.
Obese men with non-metastatic castration-resistant prostate cancer have a 21% decreased risk of death compared with normal weight men, according to a study.
Findings for both men and women with a false-positive prostate or breast cancer test result.
Increased incidence of malignant disease, specifically prostate, melanoma, pancreas, breast cancers
Sexual dysfunction was a chief complaint among survey respondents with prostate cancer.
Myocarditis with ICIs may be more common than initially thought; responds to higher steroid dosages
A novel component of an interventional program was cognitive-behavioral counseling administered in a group setting to promote behavioral change.
In a study, race independently predicted prostate cancer-specific mortality beyond a number of risk factors, including health insurance status.
Low-dose AA with low-fat breakfast had greater effect on PSA; similar effect to standard dose
Study identifies which PCa patients with positive lymph nodes may have improved survival with the addition of adjuvant radiotherapy to androgen-deprivation therapy.
Researchers concluded that a greater than 90-day interval from prostate biopsy to radical prostatectomy increases the risk of biochemical recurrence among men with Gleason 3+4 disease.
Study documents a drop in the incidence of de novo metastatic PCa from 1980 to 2011 in the United States.
New study shows that men are at lower risk of prostate cancer for years after they stop taking the medication.
In a large international trial, pre-biopsy MRI scans spared 28% of men from having to undergo a biopsy and resulted in a lower detection of clinically insignificant cancers vs standard biopsy.
Researchers observed reductions in biochemical failure and distant metastasis rates in patients who had dose-escalated radiation therapy.
However, mortality higher with conservative therapy in locally advanced, non-metastatic prostate cancer.
Findings from a large study of men in the United Kingdom do not support single PSA testing for population-based screening.
In a study, extremely dose-escalated radiotherapy combined with androgen deprivation therapy offered the best cancer-specific survival among men with Gleason 9-10 prostate cancer.
In a 12-month study, men with prostate cancer treated with ADT reported more nocturia episodes than men with prostate cancer treated with prostatectomy alone and men with no history of cancer.
Multiparametic MRI findings added to conventional clinical predictors decreases the number of false-positive biopsy results without increasing the number of clinically significant tumors left undiagnosed, study finds.
Apalutamide prolonged metastasis-free survival by 2 years compared with placebo.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)